Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever

Research output: Contribution to journalEditorial

14 Scopus citations

Abstract

First-line docetaxel treatment for metastatic castration-sensitive prostate cancer is associated with higher rates of neutropenic fever compared with those with castration-resistant disease, and prophylactic granulocyte colony-stimulating factor should be considered in those harboring risk factors for developing neutropenia.

Original languageEnglish
Pages (from-to)707-708
Number of pages2
JournalEuropean Urology
Volume70
Issue number5
DOIs
StatePublished - 2016

Fingerprint

Dive into the research topics of 'Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever'. Together they form a unique fingerprint.

Cite this